Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Prasopporn S, et al. Among authors: jirawatnotai s. Front Oncol. 2022 Nov 30;12:1021632. doi: 10.3389/fonc.2022.1021632. eCollection 2022. Front Oncol. 2022. PMID: 36531039 Free PMC article.
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Prasopporn S, et al. Among authors: jirawatnotai s. Front Oncol. 2023 Jan 6;12:1124912. doi: 10.3389/fonc.2022.1124912. eCollection 2022. Front Oncol. 2023. PMID: 36686801 Free PMC article.
Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma.
Jamnongsong S, Kueanjinda P, Buraphat P, Sakornsakolpat P, Vaeteewoottacharn K, Okada S, Jirawatnotai S, Sampattavanich S. Jamnongsong S, et al. Among authors: jirawatnotai s. iScience. 2022 Sep 23;25(10):105182. doi: 10.1016/j.isci.2022.105182. eCollection 2022 Oct 21. iScience. 2022. PMID: 36248745 Free PMC article.
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma.
Suppramote O, Prasopporn S, Aroonpruksakul S, Ponvilawan B, Makjaroen J, Suntiparpluacha M, Korphaisarn K, Charngkaew K, Chanwat R, Pisitkun T, Okada S, Sampattavanich S, Jirawatnotai S. Suppramote O, et al. Among authors: jirawatnotai s. Front Oncol. 2022 May 17;12:877194. doi: 10.3389/fonc.2022.877194. eCollection 2022. Front Oncol. 2022. PMID: 35664774 Free PMC article.
BAIAP2L1 enables cancer cell migration and facilitates phospho-Cofilin asymmetry localization in the border cells.
Pipatpanyanugoon N, Wareesawetsuwan N, Prasopporn S, Poolex W, Pisitkun T, Kaewkong W, Sampattavanich S, Jirawatnotai S. Pipatpanyanugoon N, et al. Among authors: jirawatnotai s. Cancer Commun (Lond). 2022 Jan;42(1):75-79. doi: 10.1002/cac2.12239. Epub 2021 Nov 23. Cancer Commun (Lond). 2022. PMID: 34811939 Free PMC article. No abstract available.
Overexpression of AGR2vH, an oncogenic AGR2 spliced transcript, potentiates tumorigenicity and proteomic alterations in cholangiocarcinoma cell.
Yosudjai J, Inpad C, Pothipan P, Saisomboon S, Surangkul D, Phimsen S, Hongsrichan N, Wongkham S, Jirawatnotai S, Roytrakul S, Kaewkong W. Yosudjai J, et al. Among authors: jirawatnotai s. Biosci Biotechnol Biochem. 2021 Oct 21;85(11):2263-2273. doi: 10.1093/bbb/zbab156. Biosci Biotechnol Biochem. 2021. PMID: 34494080
45 results